{"name":"ORIC Pharmaceuticals","slug":"oric","ticker":"ORIC","exchange":"NASDAQ","domain":"oricpharma.com","description":"ORIC Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for cancer, with a primary focus on overcoming drug resistance. The company's lead product, ORIC-101, is a potent and selective inhibitor of CD73, a key enzyme involved in the development of resistance to checkpoint inhibitors. ORIC-101 has shown promising results in clinical trials, and the company is working to bring this treatment to market. With a strong pipeline and a focus on addressing unmet needs in oncology, ORIC Pharmaceuticals is well-positioned for growth in the years to come.","hq":"South San Francisco, CA, USA","founded":0,"employees":"","ceo":"Jacob Chacko","sector":"Oncology / Drug Resistance","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$520M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-129468000,"cash":45669000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ORIC-101 patent cliff ($0.0B at risk)","drug":"ORIC-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"ORIC Pharmaceuticals Announces FDA Fast Track Designation for ORIC-101","summary":"ORIC Pharmaceuticals announced that the FDA has granted Fast Track designation to ORIC-101, a potent and selective inhibitor of CD73, for the treatment of patients with advanced solid tumors.","drugName":"ORIC-101","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"ORIC Pharmaceuticals reported its financial results for the third quarter of 2023, with a net loss of $23.4 million and a cash balance of $434.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-18","type":"deal","headline":"ORIC Pharmaceuticals Announces Collaboration with Merck to Develop Combination Therapy for Cancer","summary":"ORIC Pharmaceuticals announced a collaboration with Merck to develop a combination therapy for cancer, combining ORIC-101 with Merck's anti-PD-1 therapy, KEYTRUDA.","drugName":"ORIC-101","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQWEpmc3RwRWNrSzRpT204OEI1aG9kX2JWbnNwWkNHZXRSWlE4Nl9PRWpWaHRQTEpsVGw2LUFuZ0c5ZlVrcE9aU29wZHA1WE5BMzFnUk90ZERrVV9DM2otRWJTUHBnek9GQWx0b1NET3p3OWFFbUxiVnM5V05Ybk9XNWhKeUVQeWVyZGtMaVQ2emlfcVpRaDFiZWU3bVlXczdCNEpNR0dBekQ2S0RfS3BHX1l0aXhpV3phTzRGVko5UGs4ZlE?oc=5","date":"2026-04-06","type":"trial","source":"MSN","summary":"ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN","headline":"ORIC Pharma drops after early-stage trial data for prostate cancer therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFB3bENLeUsyVWdTSlpNQXJOODBJZWhqVEtUN055emlWMHhWdE80c3QyRk5lS21pMlAwREZWR2p6RFo3Nklnend6ajk1UDY5WnBBNVE?oc=5","date":"2026-04-04","type":"pipeline","source":"Yahoo Finance Australia","summary":"ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance Australia","headline":"ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPYjZyZ3VWOUw0d3BiNzlidkNRVjFNc3MzVlk0bThreWd3OW9TRHdDTjR5dGVlc1lRblF1dWtZWi1ReU95SEk5VHNDVF9Qc1MxeDVPVWtxaFIwQWg0NFh1aU0tdkxMRl9wLXBGSm9RTUlZb2JqTU1aRG5GTm1aZzVnWF8wS1FZYVl3TkRfWV9kUHF3YUZhNnc?oc=5","date":"2026-04-01","type":"pipeline","source":"Investor's Business Daily","summary":"Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges - Investor's Business Daily","headline":"Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE85YmJ4Q0hBYXo0V3VLaFJQcFhhYUJlb0pWeFFSemJBUDFnMDh3ZkItM2hmTmc1UFdkUjZEb0k0aTg0VVoyejFoS015alVkWVJSQ3ZYaUZnWmVBZWVISGfSAWNBVV95cUxOU1h3Zy1WNWJ1QVFTSWRUcGMwXzNHbmx6ZjAwYjZmWWtCM2ZNWGJ6RFlOeHg1Ulc1REtLX3ZOTXNKRnI2eWhJSnU2SmVBa3RXMGhiNm9uaXI5V2JsRF9NWHh5ejg?oc=5","date":"2026-03-31","type":"pipeline","source":"Bitget","summary":"ORIC Pharma Fails to Surpass Expected Efficacy, Prompting \"Sell the News\" Decline as Results Align with, But Do Not Surpass, Forecasts - Bitget","headline":"ORIC Pharma Fails to Surpass Expected Efficacy, Prompting \"Sell the News\" Decline as Results Align with, But Do Not Surp","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-23","type":"deal","source":"simplywall.st","summary":"ORIC Cancer Pipeline Progress And Big Pharma Partnerships Reshape Risk Profile - simplywall.st","headline":"ORIC Cancer Pipeline Progress And Big Pharma Partnerships Reshape Risk Profile","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOQVFiN2VyaGFWeEV3TGhIeng1U3BWNVZTejRheThMQXlwTlBuZ1UwTmYtcEVmZUtXNlRqSnRWeTh0aU9FX1ZYX05JNDB2bHE3OTVIY1JKVnIwS0t2dlZKbllya2tqcnRRaFQtN2t3Zm1lc0FmTTgyNGwtNDIzYzFaRUFEN0hrUVR2TFFsWmFSVHhld2Z4bXdFZ3BTRS1vVGN0MF9WcmlWbDdWZ3ppRVB1bUFnMUNRMU5Z?oc=5","date":"2026-01-16","type":"pipeline","source":"Investor's Business Daily","summary":"Oric Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily","headline":"Oric Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOdFR2OExtX3V3bmNlaHBXQWpDNkZPREdJLVYxUFZUNktNRVdsVl8zV2FIVmFRRU5sUlZ5YTNDZ2pkVU95MUs2Y2hBRXJrUmg1dWUtQ2Q0UVo5WTRmUGgxZ2NKUGttTXl4ZkV3bUFPTFItcXRqTnFkdzQ0VWtnZnFtaXVGXzNuQWp5MUgwTkJNY2JjQVlfendMRUxEb2h5R0E4YkE?oc=5","date":"2025-12-03","type":"trial","source":"The Clinical Trial Vanguard","summary":"ORIC Pharma to Present Enozertinib Data in NSCLC at ESMO - The Clinical Trial Vanguard","headline":"ORIC Pharma to Present Enozertinib Data in NSCLC at ESMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNOTRnRndKWUZwY3VIeUJRZEtKRXZkQnQ1d1prVEhFWGhVbjhjcDhRekQ5LWJ2TkFXdFBTY3NQVEhNNENTUHRZTURQZWNDUUxFMDZhcEhqSkxKN0U2RUlWMTBMMnpwYk9mbV9IQnIyVFI0MTFqLVBrZXA0YkhlcnU0bTdkczMzaGpTMG13WFRDNl8?oc=5","date":"2025-12-02","type":"trial","source":"Yahoo Finance","summary":"ORIC Pharmaceuticals (ORIC) Valuation Check as New Phase 1b Enozertinib Lung Cancer Data Approaches - Yahoo Finance","headline":"ORIC Pharmaceuticals (ORIC) Valuation Check as New Phase 1b Enozertinib Lung Cancer Data Approaches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdEdNYzVDUmJ1bFBIUFYyQnlOYUlyYi1Xd0RzcC1YWmp6UVB0bFVLVFZlRlpwVXUtcWY4d2NRRGt2WVhWdHAwY0lrVFZtNEpxOW9GU2Yxd0JJZDV2LWpRbENrTV93bE5vUnBWYUpxOHRSX2xndmxrY01QTm9ndXRabnlIWFZiSGFzaHVJaTlLS25YckNPdDZSNTdNSTBteU5kbUh4U2VNQ0E?oc=5","date":"2025-11-17","type":"trial","source":"RTTNews","summary":"ORIC Pharma Surges Ahead With ORIC-944 And Enozertinib Data Momentum - RTTNews","headline":"ORIC Pharma Surges Ahead With ORIC-944 And Enozertinib Data Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOGZ0azlUZ0Zlam02TnFvZnJuZGtVVzBTUDJ3Z3dObkEwTk1MRGpMYkNHdGVJTUwzWTdFaE11X0VPUXJ2ZkdidE9HVDR3U3ljT0pYYWV6eXpyU3QtNS1UVy02UU54MklrNlA2SURqSEhHVUJZNTA4VDU5clBMekIzSTQwLU1uZGZzSXdSR3E1ampHS0hGOUgzMmVZT0JtMjYzQ3g5TUdKYkl6QQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Pharmaceutical Executive","summary":"Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize - Pharmaceutical Executive","headline":"Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbko0UGVnQjNGME5Wcmw4a0JSNWRlZzJETlVIUnlWaXlzYjhmV1czNUVxbzFOZ1BYZldNbGJ3ZDRCS3MzYmRsRFRLbC1WYVpHM3NmWjFOcFhzUDhIRncwdHkyNWh0ZEFQUG5tOWRfeFpFVTVkSkE2cEJFZmZ1a0xuQVBLY0Z1Q3FDanNkdmpzTGVhQXI2aW5CTXVwZjVhNWxrZW9qTjRKXzE?oc=5","date":"2025-08-13","type":"pipeline","source":"Fierce Biotech","summary":"Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs - Fierce Biotech","headline":"Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs","sentiment":"neutral"}],"patents":[{"drugName":"ORIC-101","drugSlug":"cd73-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Oncology","Drug Resistance"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-129468000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":45669000,"cashHistory":[],"totalAssets":408890000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}